Abstract
123P - Evaluation of tumour microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have